{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:27:51Z","timestamp":1787851671572,"version":"build-2784847793"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270213"],"award-info":[{"award-number":["82270213"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06376-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:49:50Z","timestamp":1751410190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comprehensive machine learning analysis of PANoptosis signatures in multiple myeloma identifies prognostic and immunotherapy biomarkers"],"prefix":"10.1038","volume":"15","author":[{"given":"Yashu","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuoting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"6376_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard, F. et al. Multiple myeloma. Nat. Rev. Dis. Primers. 10, 45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7 (2024).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"6376_CR2","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar, S. V. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 99, 1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422 (2024).","journal-title":"Am. J. Hematol."},{"key":"6376_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1146\/annurev-med-050522-033815","volume":"75","author":"AL Garfall","year":"2024","unstructured":"Garfall, A. L. New biological therapies for multiple myeloma. Annu. Rev. Med. 75, 13\u201329. https:\/\/doi.org\/10.1146\/annurev-med-050522-033815 (2024).","journal-title":"Annu. Rev. Med."},{"key":"6376_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/17474086.2024.2316090","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Li, B., Chen, X., Xiong, H. & Huang, C. The effect of Immunomodulatory drugs on bone metabolism of patients with multiple myeloma. Expert Rev. Hematol. 17, 47\u201354. https:\/\/doi.org\/10.1080\/17474086.2024.2316090 (2024).","journal-title":"Expert Rev. Hematol."},{"key":"6376_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/ajh.27327","volume":"99","author":"MJ Rees","year":"2024","unstructured":"Rees, M. J. & Kumar, S. High-risk multiple myeloma: redefining genetic, clinical, and functional high-risk disease in the era of molecular medicine and immunotherapy. Am. J. Hematol. 99, 1560\u20131575. https:\/\/doi.org\/10.1002\/ajh.27327 (2024).","journal-title":"Am. J. Hematol."},{"key":"6376_CR6","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/cm9.0000000000002239","volume":"136","author":"L Gong","year":"2023","unstructured":"Gong, L., Huang, D., Shi, Y., Liang, Z. & Bu, H. Regulated cell death in cancer: from pathogenesis to treatment. Chin. Med. J. (Engl). 136, 653\u2013665. https:\/\/doi.org\/10.1097\/cm9.0000000000002239 (2023).","journal-title":"Chin. Med. J. (Engl)"},{"key":"6376_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7150\/thno.91814","volume":"14","author":"DKW Ocansey","year":"2024","unstructured":"Ocansey, D. K. W. et al. Current evidence and therapeutic implication of PANoptosis in cancer. Theranostics 14, 640\u2013661. https:\/\/doi.org\/10.7150\/thno.91814 (2024).","journal-title":"Theranostics"},{"key":"6376_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13046-024-03089-6","volume":"43","author":"L Gao","year":"2024","unstructured":"Gao, L., Shay, C. & Teng, Y. Cell death shapes cancer immunity: spotlighting PANoptosis. J. Exp. Clin. Cancer Res. 43, 168. https:\/\/doi.org\/10.1186\/s13046-024-03089-6 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"6376_CR9","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/s41417-024-00765-9","volume":"31","author":"J Gao","year":"2024","unstructured":"Gao, J. et al. PANoptosis: bridging apoptosis, pyroptosis, and necroptosis in cancer progression and treatment. Cancer Gene Ther. 31, 970\u2013983. https:\/\/doi.org\/10.1038\/s41417-024-00765-9 (2024).","journal-title":"Cancer Gene Ther."},{"key":"6376_CR10","doi-asserted-by":"publisher","first-page":"217254","DOI":"10.1016\/j.canlet.2024.217254","volume":"604","author":"YT Tan","year":"2024","unstructured":"Tan, Y. T. et al. WTAP weakens oxaliplatin chemosensitivity of colorectal cancer by preventing PANoptosis. Cancer Lett. 604, 217254. https:\/\/doi.org\/10.1016\/j.canlet.2024.217254 (2024).","journal-title":"Cancer Lett."},{"key":"6376_CR11","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.7150\/ijbs.85236","volume":"19","author":"Y Cai","year":"2023","unstructured":"Cai, Y. et al. Activation of STING by SAMHD1 deficiency promotes PANoptosis and enhances efficacy of PD-L1 Blockade in diffuse large B-cell lymphoma. Int. J. Biol. Sci. 19, 4627\u20134643. https:\/\/doi.org\/10.7150\/ijbs.85236 (2023).","journal-title":"Int. J. Biol. Sci."},{"key":"6376_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.4049\/immunohorizons.2100059","volume":"5","author":"RKS Malireddi","year":"2021","unstructured":"Malireddi, R. K. S. et al. Inflammatory cell death, panoptosis, mediated by cytokines in diverse Cancer lineages inhibits tumor growth. Immunohorizons 5, 568\u2013580. https:\/\/doi.org\/10.4049\/immunohorizons.2100059 (2021).","journal-title":"Immunohorizons"},{"key":"6376_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12967-024-04955-9","volume":"22","author":"H Huang","year":"2024","unstructured":"Huang, H. et al. A multi-dimensional approach to unravel the intricacies of lactylation related signature for prognostic and therapeutic insight in colorectal cancer. J. Transl Med. 22, 211. https:\/\/doi.org\/10.1186\/s12967-024-04955-9 (2024).","journal-title":"J. Transl Med."},{"key":"6376_CR14","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1038\/s41598-024-59464-y","volume":"14","author":"J Wang","year":"2024","unstructured":"Wang, J. et al. NET-related gene signature for predicting AML prognosis. Sci. Rep. 14, 9115. https:\/\/doi.org\/10.1038\/s41598-024-59464-y (2024).","journal-title":"Sci. Rep."},{"key":"6376_CR15","doi-asserted-by":"publisher","first-page":"876981","DOI":"10.3389\/fonc.2022.876981","volume":"12","author":"D Li","year":"2022","unstructured":"Li, D. et al. A distinct lipid metabolism signature of acute myeloid leukemia with prognostic value. Front. Oncol. 12, 876981. https:\/\/doi.org\/10.3389\/fonc.2022.876981 (2022).","journal-title":"Front. Oncol."},{"key":"6376_CR16","doi-asserted-by":"publisher","first-page":"109019","DOI":"10.1016\/j.clim.2022.109019","volume":"238","author":"H Pan","year":"2022","unstructured":"Pan, H., Pan, J., Li, P. & Gao, J. Characterization of PANoptosis patterns predicts survival and immunotherapy response in gastric cancer. Clin. Immunol. 238, 109019. https:\/\/doi.org\/10.1016\/j.clim.2022.109019 (2022).","journal-title":"Clin. Immunol."},{"key":"6376_CR17","doi-asserted-by":"publisher","first-page":"1198713","DOI":"10.3389\/fnmol.2023.1198713","volume":"16","author":"J Song","year":"2023","unstructured":"Song, J., Xu, Z., Fan, Q., Sun, Y. & Lin, X. The PANoptosis-related signature indicates the prognosis and tumor immune infiltration features of gliomas. Front. Mol. Neurosci. 16, 1198713. https:\/\/doi.org\/10.3389\/fnmol.2023.1198713 (2023).","journal-title":"Front. Mol. Neurosci."},{"key":"6376_CR18","doi-asserted-by":"publisher","first-page":"1210456","DOI":"10.3389\/fcell.2023.1210456","volume":"11","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma. Front. Cell. Dev. Biol. 11, 1210456. https:\/\/doi.org\/10.3389\/fcell.2023.1210456 (2023).","journal-title":"Front. Cell. Dev. Biol."},{"key":"6376_CR19","doi-asserted-by":"publisher","first-page":"9824","DOI":"10.1038\/s41598-024-60441-8","volume":"14","author":"P Yang","year":"2024","unstructured":"Yang, P. et al. Identification of PANoptosis-related biomarkers and analysis of prognostic values in head and neck squamous cell carcinoma. Sci. Rep. 14, 9824. https:\/\/doi.org\/10.1038\/s41598-024-60441-8 (2024).","journal-title":"Sci. Rep."},{"key":"6376_CR20","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013d677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"6376_CR21","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward Understanding the origin and evolution of cellular organisms. Protein Sci. 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci."},{"key":"6376_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res."},{"key":"6376_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal. Transduct. Target. Ther. 8, 9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"6376_CR24","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.ctrv.2023.102614","volume":"120","author":"M Borgeaud","year":"2023","unstructured":"Borgeaud, M. et al. Novel targets for immune-checkpoint Inhibition in cancer. Cancer Treat. Rev. 120, 102614. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102614 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"6376_CR25","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.4161\/cc.26062","volume":"12","author":"K Do","year":"2013","unstructured":"Do, K., Doroshow, J. H. & Kummar, S. Wee1 kinase as a target for cancer therapy. Cell. Cycle. 12, 3159\u20133164. https:\/\/doi.org\/10.4161\/cc.26062 (2013).","journal-title":"Cell. Cycle"},{"key":"6376_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41571-024-00863-5","volume":"21","author":"NYL Ngoi","year":"2024","unstructured":"Ngoi, N. Y. L. et al. Targeting ATR in patients with cancer. Nat. Rev. Clin. Oncol. 21, 278\u2013293. https:\/\/doi.org\/10.1038\/s41571-024-00863-5 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"6376_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.bcp.2019.04.022","volume":"164","author":"W Qi","year":"2019","unstructured":"Qi, W. et al. Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. Biochem. Pharmacol. 164, 273\u2013282. https:\/\/doi.org\/10.1016\/j.bcp.2019.04.022 (2019).","journal-title":"Biochem. Pharmacol."},{"key":"6376_CR28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/ijc.30373","volume":"140","author":"HJ Kim","year":"2017","unstructured":"Kim, H. J. et al. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells. Int. J. Cancer. 140, 109\u2013119. https:\/\/doi.org\/10.1002\/ijc.30373 (2017).","journal-title":"Int. J. Cancer"},{"key":"6376_CR29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1535-7163.Mct-16-0378","volume":"16","author":"A Min","year":"2017","unstructured":"Min, A. et al. AZD6738, A novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric Cancer cells. Mol. Cancer Ther. 16, 566\u2013577. https:\/\/doi.org\/10.1158\/1535-7163.Mct-16-0378 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"6376_CR30","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1158\/1535-7163.Mct-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez, Y. et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol. Cancer Ther. 17, 1670\u20131682. https:\/\/doi.org\/10.1158\/1535-7163.Mct-18-0010 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"6376_CR31","doi-asserted-by":"publisher","unstructured":"Sheng, H. et al. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J. Immunother Cancer. 8 https:\/\/doi.org\/10.1136\/jitc-2019-000340 (2020).","DOI":"10.1136\/jitc-2019-000340"},{"key":"6376_CR32","doi-asserted-by":"publisher","unstructured":"Hur, J. et al. Synergism of AZD6738, an ATR inhibitor, in combination with belotecan, a camptothecin analogue, in Chemotherapy-Resistant ovarian Cancer. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22031223 (2021).","DOI":"10.3390\/ijms22031223"},{"key":"6376_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.14715\/cmb\/2020.66.4.6","volume":"66","author":"MT Islam","year":"2020","unstructured":"Islam, M. T. et al. Biological activities of sinularin: A literature-based review. Cell. Mol. Biol. (Noisy-le-grand). 66, 33\u201336 (2020).","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"6376_CR34","doi-asserted-by":"publisher","unstructured":"Hsu, S. Y. et al. Sinularin induces oxidative Stress-Mediated apoptosis and mitochondrial dysfunction, and inhibits angiogenesis in glioblastoma cells. Antioxid. (Basel). 11. https:\/\/doi.org\/10.3390\/antiox11081433 (2022).","DOI":"10.3390\/antiox11081433"},{"key":"6376_CR35","doi-asserted-by":"publisher","first-page":"116011","DOI":"10.1016\/j.bcp.2023.116011","volume":"220","author":"XY Meng","year":"2024","unstructured":"Meng, X. Y. et al. Sinularin stabilizes FOXO3 protein to trigger prostate cancer cell intrinsic apoptosis. Biochem. Pharmacol. 220, 116011. https:\/\/doi.org\/10.1016\/j.bcp.2023.116011 (2024).","journal-title":"Biochem. Pharmacol."},{"key":"6376_CR36","doi-asserted-by":"publisher","first-page":"e2300640","DOI":"10.1002\/adbi.202300640","volume":"8","author":"Y Huang","year":"2024","unstructured":"Huang, Y. et al. BET inhibitor JQ1 selectively reduce Tregs by upregulating STAT3 and suppressing PD-1 expression in patients with multiple myeloma. Adv. Biol. (Weinh). 8, e2300640. https:\/\/doi.org\/10.1002\/adbi.202300640 (2024).","journal-title":"Adv. Biol. (Weinh)"},{"key":"6376_CR37","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/0008-5472.Can-23-1632","volume":"84","author":"L Xia","year":"2024","unstructured":"Xia, L. et al. Osimertinib covalently binds to CD34 and eliminates myeloid leukemia stem\/progenitor cells. Cancer Res. 84, 479\u2013492. https:\/\/doi.org\/10.1158\/0008-5472.Can-23-1632 (2024).","journal-title":"Cancer Res."},{"key":"6376_CR38","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt, M., Kort\u00fcm, K. M., Goldschmidt, H. & Merz, M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica 109, 2420\u20132435. https:\/\/doi.org\/10.3324\/haematol.2023.283058 (2024).","journal-title":"Haematologica"},{"key":"6376_CR39","doi-asserted-by":"publisher","unstructured":"Tang, L., Zhang, W., Zhang, Y., Deng, W. & Zhao, M. Machine Learning-Based integrated analysis of PANoptosis patterns in acute myeloid leukemia reveals a signature predicting survival and immunotherapy. Int. J. Clin. Pract. 2024 (5113990). https:\/\/doi.org\/10.1155\/2024\/5113990 (2024).","DOI":"10.1155\/2024\/5113990"},{"key":"6376_CR40","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1016\/j.csbj.2021.07.038","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang, Y. & Kanneganti, T. D. From pyroptosis, apoptosis and necroptosis to panoptosis: A mechanistic compendium of programmed cell death pathways. Comput. Struct. Biotechnol. J. 19, 4641\u20134657. https:\/\/doi.org\/10.1016\/j.csbj.2021.07.038 (2021).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"6376_CR41","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/imr.13279","volume":"321","author":"X Sun","year":"2024","unstructured":"Sun, X. et al. Mechanisms, biology, and role in disease. Immunol. Rev. 321, 246\u2013262. https:\/\/doi.org\/10.1111\/imr.13279 (2024).","journal-title":"Immunol. Rev."},{"key":"6376_CR42","doi-asserted-by":"publisher","unstructured":"Oh, Y. T. & Sun, S. Y. Regulation of Cancer Metastasis by TRAIL\/Death Receptor Signaling. Biomolecules 11, 499. https:\/\/doi.org\/10.3390\/biom11040499 (2021).","DOI":"10.3390\/biom11040499"},{"key":"6376_CR43","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.4049\/jimmunol.168.3.1356","volume":"168","author":"E Cretney","year":"2002","unstructured":"Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356\u20131361. https:\/\/doi.org\/10.4049\/jimmunol.168.3.1356 (2002).","journal-title":"J. Immunol."},{"key":"6376_CR44","doi-asserted-by":"publisher","first-page":"5586","DOI":"10.4049\/jimmunol.175.9.5586","volume":"175","author":"N Zerafa","year":"2005","unstructured":"Zerafa, N. et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175, 5586\u20135590. https:\/\/doi.org\/10.4049\/jimmunol.175.9.5586 (2005).","journal-title":"J. Immunol."},{"key":"6376_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1172\/jci29900","volume":"118","author":"N Finnberg","year":"2008","unstructured":"Finnberg, N., Klein-Szanto, A. J. & El-Deiry, W. S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest. 118, 111\u2013123. https:\/\/doi.org\/10.1172\/jci29900 (2008).","journal-title":"J. Clin. Invest."},{"key":"6376_CR46","doi-asserted-by":"publisher","first-page":"41324","DOI":"10.18632\/oncotarget.5847","volume":"6","author":"YT Oh","year":"2015","unstructured":"Oh, Y. T. et al. Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8\/TRAF2-mediated signaling. Oncotarget 6, 41324\u201341338. https:\/\/doi.org\/10.18632\/oncotarget.5847 (2015).","journal-title":"Oncotarget"},{"key":"6376_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40265-024-02004-9","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon, S. & Aponermin First Approval Drugs 84, 459\u2013466 https:\/\/doi.org\/10.1007\/s40265-024-02004-9 (2024).","journal-title":"First Approval Drugs"},{"key":"6376_CR48","doi-asserted-by":"publisher","unstructured":"Ranjan, K. & Pathak, C. Cellular dynamics of Fas-Associated death domain in the regulation of Cancer and inflammation. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms25063228 (2024).","DOI":"10.3390\/ijms25063228"},{"key":"6376_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/nature09075","volume":"465","author":"L Chen","year":"2010","unstructured":"Chen, L. et al. CD95 promotes tumour growth. Nature 465, 492\u2013496. https:\/\/doi.org\/10.1038\/nature09075 (2010).","journal-title":"Nature"},{"key":"6376_CR50","doi-asserted-by":"publisher","first-page":"5238","DOI":"10.1038\/ncomms6238","volume":"5","author":"P Ceppi","year":"2014","unstructured":"Ceppi, P. et al. CD95 and CD95L promote and protect cancer stem cells. Nat. Commun. 5, 5238. https:\/\/doi.org\/10.1038\/ncomms6238 (2014).","journal-title":"Nat. Commun."},{"key":"6376_CR51","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1038\/cdd.2014.217","volume":"22","author":"M Teodorczyk","year":"2015","unstructured":"Teodorczyk, M. et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell. Death Differ. 22, 1192\u20131202. https:\/\/doi.org\/10.1038\/cdd.2014.217 (2015).","journal-title":"Cell. Death Differ."},{"key":"6376_CR52","doi-asserted-by":"publisher","first-page":"e2209","DOI":"10.1038\/cddis.2016.102","volume":"7","author":"M Drachsler","year":"2016","unstructured":"Drachsler, M. et al. CD95 maintains stem cell-like and non-classical EMT programs in primary human glioblastoma cells. Cell. Death Dis. 7, e2209. https:\/\/doi.org\/10.1038\/cddis.2016.102 (2016).","journal-title":"Cell. Death Dis."},{"key":"6376_CR53","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00018-020-03656-y","volume":"78","author":"A Ciesielska","year":"2021","unstructured":"Ciesielska, A., Matyjek, M. & Kwiatkowska, K. TLR4 and CD14 trafficking and its influence on LPS-induced pro-inflammatory signaling. Cell. Mol. Life Sci. 78, 1233\u20131261. https:\/\/doi.org\/10.1007\/s00018-020-03656-y (2021).","journal-title":"Cell. Mol. Life Sci."},{"key":"6376_CR54","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.cell.2007.08.002","volume":"130","author":"HM Kim","year":"2007","unstructured":"Kim, H. M. et al. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell 130, 906\u2013917. https:\/\/doi.org\/10.1016\/j.cell.2007.08.002 (2007).","journal-title":"Cell"},{"key":"6376_CR55","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.7150\/ijbs.39098","volume":"16","author":"V Rajamanickam","year":"2020","unstructured":"Rajamanickam, V. et al. Selective targeting of the TLR4 co-receptor, MD2, prevents colon cancer growth and lung metastasis. Int. J. Biol. Sci. 16, 1288\u20131302. https:\/\/doi.org\/10.7150\/ijbs.39098 (2020).","journal-title":"Int. J. Biol. Sci."},{"key":"6376_CR56","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/s41388-023-02925-x","volume":"43","author":"MG Ferrari","year":"2024","unstructured":"Ferrari, M. G. et al. Myeloid differentiation factor-2\/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target. Oncogene 43, 484\u2013494. https:\/\/doi.org\/10.1038\/s41388-023-02925-x (2024).","journal-title":"Oncogene"},{"key":"6376_CR57","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/jnci\/95.4.316","volume":"95","author":"M Okamoto","year":"2003","unstructured":"Okamoto, M. et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by Streptococcal agent OK-432. J. Natl. Cancer Inst. 95, 316\u2013326. https:\/\/doi.org\/10.1093\/jnci\/95.4.316 (2003).","journal-title":"J. Natl. Cancer Inst."},{"key":"6376_CR58","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-020-00311-7","volume":"5","author":"N Xie","year":"2020","unstructured":"Xie, N. et al. NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential. Signal. Transduct. Target. Ther. 5, 227. https:\/\/doi.org\/10.1038\/s41392-020-00311-7 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"6376_CR59","doi-asserted-by":"publisher","first-page":"7131","DOI":"10.1039\/d1an01769a","volume":"146","author":"A Karpi\u0144ska","year":"2021","unstructured":"Karpi\u0144ska, A. et al. Quantitative analysis of biochemical processes in living cells at a single-molecule level: a case of olaparib-PARP1 (DNA repair protein) interactions. Analyst 146, 7131\u20137143. https:\/\/doi.org\/10.1039\/d1an01769a (2021).","journal-title":"Analyst"},{"key":"6376_CR60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1158\/1541-7786.Mcr-14-0422","volume":"13","author":"N Muvarak","year":"2015","unstructured":"Muvarak, N. et al. c-MYC generates repair errors via increased transcription of Alternative-NHEJ factors, LIG3 and PARP1, in tyrosine Kinase-Activated leukemias. Mol. Cancer Res. 13, 699\u2013712. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-14-0422 (2015).","journal-title":"Mol. Cancer Res."},{"key":"6376_CR61","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/ajh.2830370402","volume":"37","author":"T Tomoda","year":"1991","unstructured":"Tomoda, T. et al. Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma. Am. J. Hematol. 37, 223\u2013227. https:\/\/doi.org\/10.1002\/ajh.2830370402 (1991).","journal-title":"Am. J. Hematol."},{"key":"6376_CR62","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1541-7786.Mcr-14-0337","volume":"13","author":"EA Newman","year":"2015","unstructured":"Newman, E. A. et al. Alternative NHEJ pathway components are therapeutic targets in High-Risk neuroblastoma. Mol. Cancer Res. 13, 470\u2013482. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-14-0337 (2015).","journal-title":"Mol. Cancer Res."},{"key":"6376_CR63","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.21873\/anticanres.15014","volume":"41","author":"CB Machado","year":"2021","unstructured":"Machado, C. B. et al. PARP1 is overexpressed in hematological malignant cell lines: A framework for experimental oncology. Anticancer Res. 41, 2397\u20132402. https:\/\/doi.org\/10.21873\/anticanres.15014 (2021).","journal-title":"Anticancer Res."},{"key":"6376_CR64","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3324\/haematol.2022.282399","volume":"108","author":"M Thomas","year":"2023","unstructured":"Thomas, M. et al. PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant. Haematologica 108, 2155\u20132166. https:\/\/doi.org\/10.3324\/haematol.2022.282399 (2023).","journal-title":"Haematologica"},{"key":"6376_CR65","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly, F. J., Fawkes, M., Dagg, R. A., Blackford, A. N. & Tarsounas, M. Targeting DNA damage response pathways in cancer. Nat. Rev. Cancer. 23, 78\u201394. https:\/\/doi.org\/10.1038\/s41568-022-00535-5 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"6376_CR66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13048-023-01094-5","volume":"16","author":"Y Wu","year":"2023","unstructured":"Wu, Y., Xu, S., Cheng, S., Yang, J. & Wang, Y. Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status. J. Ovarian Res. 16, 6. https:\/\/doi.org\/10.1186\/s13048-023-01094-5 (2023).","journal-title":"J. Ovarian Res."},{"key":"6376_CR67","doi-asserted-by":"publisher","first-page":"4066","DOI":"10.1158\/1078-0432.Ccr-18-0042","volume":"24","author":"G Ison","year":"2018","unstructured":"Ison, G. et al. FDA approval summary: niraparib for the maintenance treatment of patients with recurrent ovarian Cancer in response to Platinum-Based chemotherapy. Clin. Cancer Res. 24, 4066\u20134071. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0042 (2018).","journal-title":"Clin. Cancer Res."},{"key":"6376_CR68","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.1182\/bloodadvances.2021004638","volume":"5","author":"CN Kontandreopoulou","year":"2021","unstructured":"Kontandreopoulou, C. N., Diamantopoulos, P. T., Tiblalexi, D., Giannakopoulou, N. & Viniou, N. A. PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome. Blood Adv. 5, 4794\u20134805. https:\/\/doi.org\/10.1182\/bloodadvances.2021004638 (2021).","journal-title":"Blood Adv."},{"key":"6376_CR69","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.freeradbiomed.2024.12.052","volume":"228","author":"H Zhang","year":"2025","unstructured":"Zhang, H. et al. PARP1 inhibitor niraparib exerts synergistic antimyeloma effect with bortezomib through inducing DNA damage and inhibiting DNA repair. Free Radic Biol. Med. 228, 392\u2013402. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.12.052 (2025).","journal-title":"Free Radic Biol. Med."},{"key":"6376_CR70","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1471-2148-14-10","volume":"14","author":"L Cao","year":"2014","unstructured":"Cao, L. et al. Phylogenetic analysis of CDK and Cyclin proteins in premetazoan lineages. BMC Evol. Biol. 14, 10. https:\/\/doi.org\/10.1186\/1471-2148-14-10 (2014).","journal-title":"BMC Evol. Biol."},{"key":"6376_CR71","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/jnc.13070","volume":"133","author":"C Alqu\u00e9zar","year":"2015","unstructured":"Alqu\u00e9zar, C. et al. Targeting Cyclin D3\/CDK6 activity for treatment of parkinson\u2019s disease. J. Neurochem. 133, 886\u2013897. https:\/\/doi.org\/10.1111\/jnc.13070 (2015).","journal-title":"J. Neurochem"},{"key":"6376_CR72","doi-asserted-by":"publisher","first-page":"105115","DOI":"10.1016\/j.neuint.2021.105115","volume":"148","author":"N Malhotra","year":"2021","unstructured":"Malhotra, N., Gupta, R. & Kumar, P. Pharmacological relevance of CDK inhibitors in alzheimer\u2019s disease. Neurochem Int. 148, 105115. https:\/\/doi.org\/10.1016\/j.neuint.2021.105115 (2021).","journal-title":"Neurochem Int."},{"key":"6376_CR73","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang, Q., Bode, A. M. & Zhang, T. Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol. 7, 58. https:\/\/doi.org\/10.1038\/s41698-023-00407-7 (2023).","journal-title":"NPJ Precis Oncol."},{"key":"6376_CR74","doi-asserted-by":"publisher","first-page":"23067","DOI":"10.18632\/aging.104066","volume":"12","author":"D Wu","year":"2020","unstructured":"Wu, D. et al. CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient. Aging (Albany NY). 12, 23067\u201323081. https:\/\/doi.org\/10.18632\/aging.104066 (2020).","journal-title":"Aging (Albany NY)"},{"key":"6376_CR75","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1634\/theoncologist.5-5-435","volume":"5","author":"DS Goodsell","year":"2000","unstructured":"Goodsell, D. S. The molecular perspective: caspases. Oncologist 5, 435\u2013436. https:\/\/doi.org\/10.1634\/theoncologist.5-5-435 (2000).","journal-title":"Oncologist"},{"key":"6376_CR76","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2174\/1389203724666230227115305","volume":"24","author":"N Srivastava","year":"2023","unstructured":"Srivastava, N. & Saxena, A. K. Caspase-3 activators as anticancer agents. Curr. Protein Pept. Sci. 24, 783\u2013804. https:\/\/doi.org\/10.2174\/1389203724666230227115305 (2023).","journal-title":"Curr. Protein Pept. Sci."},{"key":"6376_CR77","doi-asserted-by":"publisher","unstructured":"Green, D. R. Caspase activation and Inhibition. Cold Spring Harb Perspect. Biol. 14 https:\/\/doi.org\/10.1101\/cshperspect.a041020 (2022).","DOI":"10.1101\/cshperspect.a041020"},{"key":"6376_CR78","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41420-020-00349-0","volume":"6","author":"M Jiang","year":"2020","unstructured":"Jiang, M., Qi, L., Li, L. & Li, Y. The caspase-3\/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer. Cell. Death Discov. 6, 112. https:\/\/doi.org\/10.1038\/s41420-020-00349-0 (2020).","journal-title":"Cell. Death Discov"},{"key":"6376_CR79","doi-asserted-by":"publisher","first-page":"ra13","DOI":"10.1126\/scisignal.2000634","volume":"3","author":"F Li","year":"2010","unstructured":"Li, F. et al. Apoptotic cells activate the phoenix rising pathway to promote wound healing and tissue regeneration. Sci. Signal. 3, ra13. https:\/\/doi.org\/10.1126\/scisignal.2000634 (2010).","journal-title":"Sci. Signal."},{"key":"6376_CR80","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ydbio.2009.09.015","volume":"338","author":"J Pellettieri","year":"2010","unstructured":"Pellettieri, J. et al. Cell death and tissue remodeling in planarian regeneration. Dev. Biol. 338, 76\u201385. https:\/\/doi.org\/10.1016\/j.ydbio.2009.09.015 (2010).","journal-title":"Dev. Biol."},{"key":"6376_CR81","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.devcel.2009.07.014","volume":"17","author":"S Chera","year":"2009","unstructured":"Chera, S. et al. Apoptotic cells provide an unexpected source of Wnt3 signaling to drive hydra head regeneration. Dev. Cell. 17, 279\u2013289. https:\/\/doi.org\/10.1016\/j.devcel.2009.07.014 (2009).","journal-title":"Dev. Cell."},{"key":"6376_CR82","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/onc.2011.459","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi, L., Kepp, O. & Kroemer, G. Caspase-3 and prostaglandins signal for tumor regrowth in cancer therapy. Oncogene 31, 2805\u20132808. https:\/\/doi.org\/10.1038\/onc.2011.459 (2012).","journal-title":"Oncogene"},{"key":"6376_CR83","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nm.2385","volume":"17","author":"Q Huang","year":"2011","unstructured":"Huang, Q. et al. Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nat. Med. 17, 860\u2013866. https:\/\/doi.org\/10.1038\/nm.2385 (2011).","journal-title":"Nat. Med."},{"key":"6376_CR84","doi-asserted-by":"publisher","first-page":"107805","DOI":"10.1016\/j.pharmthera.2021.107805","volume":"223","author":"L Treps","year":"2021","unstructured":"Treps, L., Faure, S. & Clere, N. Vasculogenic mimicry, a complex and devious process favoring tumorigenesis - Interest in making it a therapeutic target. Pharmacol. Ther. 223, 107805. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107805 (2021).","journal-title":"Pharmacol. Ther."},{"key":"6376_CR85","doi-asserted-by":"publisher","first-page":"29357","DOI":"10.1074\/jbc.M513105200","volume":"281","author":"X Zhao","year":"2006","unstructured":"Zhao, X. et al. Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells. J. Biol. Chem. 281, 29357\u201329368. https:\/\/doi.org\/10.1074\/jbc.M513105200 (2006).","journal-title":"J. Biol. Chem."},{"key":"6376_CR86","doi-asserted-by":"publisher","first-page":"9121","DOI":"10.1158\/0008-5472.Can-04-4344","volume":"65","author":"M Mukai","year":"2005","unstructured":"Mukai, M. et al. Cross talk between apoptosis and invasion signaling in cancer cells through caspase-3 activation. Cancer Res. 65, 9121\u20139125. https:\/\/doi.org\/10.1158\/0008-5472.Can-04-4344 (2005).","journal-title":"Cancer Res."},{"key":"6376_CR87","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/CMR.0b013e3283625498","volume":"23","author":"YR Liu","year":"2013","unstructured":"Liu, Y. R. et al. Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells. Melanoma Res. 23, 243\u2013253. https:\/\/doi.org\/10.1097\/CMR.0b013e3283625498 (2013).","journal-title":"Melanoma Res."},{"key":"6376_CR88","doi-asserted-by":"publisher","first-page":"216894","DOI":"10.1016\/j.canlet.2024.216894","volume":"591","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani, M. et al. Unraveling the tumor microenvironment: insights into cancer metastasis and therapeutic strategies. Cancer Lett. 591, 216894. https:\/\/doi.org\/10.1016\/j.canlet.2024.216894 (2024).","journal-title":"Cancer Lett."},{"key":"6376_CR89","doi-asserted-by":"publisher","first-page":"1483454","DOI":"10.3389\/fonc.2024.1483454","volume":"14","author":"X Yin","year":"2024","unstructured":"Yin, X. et al. Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy. Front. Oncol. 14, 1483454. https:\/\/doi.org\/10.3389\/fonc.2024.1483454 (2024).","journal-title":"Front. Oncol."},{"key":"6376_CR90","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","volume":"11","author":"W Zhang","year":"2020","unstructured":"Zhang, W. et al. Advances in Anti-Tumor treatments targeting the CD47\/SIRP\u03b1 Axis. Front. Immunol. 11, 18. https:\/\/doi.org\/10.3389\/fimmu.2020.00018 (2020).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06376-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06376-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06376-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T22:49:51Z","timestamp":1751410191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06376-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":90,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6376"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06376-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures involving human participants were approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Approval No. RG2023-306-02) and performed in accordance with ethical standards. Written informed consent was obtained from all individual participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"22478"}}